MyMD Pharmaceuticals, Inc. announced that preclinical data from a study, conducted in partnership with Charles River Laboratories International, Inc., has been accepted for presentation at the upcoming Society of Toxicology (SOT) 2023 Annual Meeting. Poster #3046/P148 "A Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNF-, MYMD-1 (Isomyosamine) Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis," is scheduled for poster presentation on March 20, 2023, at 9:00 AM CT. MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

MyMD plans to give guidance on the early-stage trials for rheumatoid arthritis (RA) as it develops. MyMD-1 is currently being evaluated in a Phase 2 study for sarcopenia/frailty, a result of the aging process. It has the potential to become the first drug approved by FDA for that condition.

The company plans to complete the Phase 2 sarcopenia trial and share data in the near future.